• / Free eNewsletters & Magazine
  • / My Account
Home>WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes

WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes

WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes

10/05/2017

WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based on Marrow-Infiltrating Lymphocytes

-- Lead program currently in randomized, multi-center trial in patients with high-risk multiple myeloma --

-- Additional programs using MILs™ in solid tumors advancing to the clinic --

-- Company funded and incubated by Domain Associates, FOXKISER and Silver Rock LLC --

WindMIL Therapeutics, a clinical stage company developing Marrow-Infiltrating Lymphocytes (MILs™) for cancer immunotherapy, today presented its novel approach to harnessing a patient’s immune system to treat solid and liquid cancers at The Cell & Gene Meeting on the Mesa in La Jolla, CA.

Memory T cells are believed to generate the immune system’s most effective killers, and the role of the bone marrow in the formation and maintenance of memory T cells has become increasingly well-understood. Consistent with this understanding, WindMIL’s co-founders Ivan Borrello, M.D., and Kimberly Noonan, Ph.D., have demonstrated that the bone marrow of patients with both hematologic and solid tumors contain memory T cells that can recognize and destroy tumor cells. They have worked at the Johns Hopkins University School of Medicine for over a decade to perfect the activation and expansion of the cells they termed ‘MILs™’. WindMIL has exclusively licensed intellectual property related to this pioneering work by Drs. Borrello and Noonan.

“MILs™ represent a novel class of cell therapy,” says Brian Halak, Ph.D., founding Chief Executive Officer of WindMIL. “Owing to their derivation from the bone marrow, a natural reservoir for memory T cells, MILs™ are marked by inherent tumor specificity, low toxicity, and long-term persistence. We believe that our ability to harness this long-term memory component is what differentiates MIL™-therapy from other cell-therapy approaches, which rely predominantly on T cells found in the periphery.”

WindMIL Therapeutics’ lead program is currently enrolling patients in a Phase 2b clinical trial for patients in high risk myeloma (clinicaltrials.gov ID#NCT01858558) and is supported by the Leukemia and Lymphoma Society.

©2017 Morningstar Advisor. All right reserved.